Skip to content

520A.T

Nxera Pharma Co.,Ltd.

グロース · 医薬品 · 医薬品 · JP

JPY 419.00
−9.31%
Ask drillr

Income statement

Metric2026
Revenue
Total Revenue—
Cost of Revenue—
Gross Profit—
Operating Expenses
R&D Expense—
SG&A Expense—
General & Admin Expense—
Selling & Marketing Expense—
Other Expenses—
Total Operating Expenses—
Cost and Expenses—
Operating Income (EBIT)(3.7B)
Non-Operating
Interest Income2.9M
Interest Expense—
Net Interest Income—
Other Non-Op Income/Expense1.1B
Non-Operating Income (excl Interest)1.1B
EBT (Pre-Tax Income)(2.5B)
Income Tax Expense1.1M
Bottom Line
Net Income(2.5B)
Earnings from Cont. Ops—
Earnings from Discont. Ops—
Bottom Line Net Income(2.5B)
Per Share
Basic EPS(¥195)
Diluted EPS(¥195)
Revenue Per Share—
Shares
Basic Shares Outstanding12.6M
Diluted Shares Outstanding—
Profitability Metrics
EBITDA(3.7B)
D&A1.2M
EBIT(3.7B)

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026